Case Study: Emerging Biopharma Company achieves comprehensive rare‑disease insights and 61% increased account coverage with IQVIA data triangulation

How to Generate Business Insights in Rare Diseases and Niche Oncology Through Data Triangulation

Emerging Biopharma Company was preparing to launch a treatment for a rare cardiology disease and needed a clearer view of patient profiles, treating HCPs and the market landscape to shape its go-to-market strategy. IQVIA was engaged to address this data-scarce challenge using its proprietary assets — including IQVIA Real World Data, MIDAS, BioNLP Explorer, PharmaSpectra and OneKey — and its machine learning and predictive analytics expertise.

IQVIA connected and triangulated those data sources into an enriched unified dataset, applied clustering and segmentation algorithms to identify best-fit patient and HCP segments, and co‑designed a hybrid engagement model with the client. As a result, the Emerging Biopharma Company assessed 1,600+ non-identified patient profiles and 300+ HCPs, identified patient segments unresponsive to the current standard of care, characterized high-interest HCPs, published scientific findings, and increased account coverage by 61% through the IQVIA-designed engagement model.